- Home
- Publications
- Publication Search
- Publication Details
Title
Bevacizumab in glioblastoma multiforme
Authors
Keywords
-
Journal
Expert Review of Anticancer Therapy
Volume 12, Issue 1, Pages 9-18
Publisher
Informa UK Limited
Online
2011-12-09
DOI
10.1586/era.11.179
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Clinical outcome with bevacizumab in patients with recurrent high-grade glioma treated outside clinical trials
- (2011) Silvia Hofer et al. ACTA ONCOLOGICA
- AVAglio: Phase 3 trial of bevacizumab plus temozolomide and radiotherapy in newly diagnosed glioblastoma multiforme
- (2011) O. L. Chinot et al. ADVANCES IN THERAPY
- Isolated Diffusion Restriction Precedes the Development of Enhancing Tumor in a Subset of Patients with Glioblastoma
- (2011) A. Gupta et al. AMERICAN JOURNAL OF NEURORADIOLOGY
- Approval denied by the European Medicines Agency (EMA) for bevacizumab in the treatment of high-grade glioma recurrence: a good idea or a grave error?
- (2011) Carmen Balañá et al. Clinical & Translational Oncology
- Is Computed Tomography Simulation Associated With Improved Survival, or Is This Finding a Result of Confounding Variables?
- (2011) Matthew Koshy JOURNAL OF CLINICAL ONCOLOGY
- Cigarette Smoking Is Associated With Advanced Renal Cell Carcinoma
- (2011) Matvey Tsivian et al. JOURNAL OF CLINICAL ONCOLOGY
- DNA repair gene polymorphisms and risk of adult meningioma, glioma, and acoustic neuroma
- (2011) P. Rajaraman et al. NEURO-ONCOLOGY
- Bevacizumab does not increase the risk of remote relapse in malignant glioma
- (2010) Antje Wick et al. ANNALS OF NEUROLOGY
- Bevacizumab and dose-intense temozolomide in recurrent high-grade glioma
- (2010) J. J. C. Verhoeff et al. ANNALS OF ONCOLOGY
- A phase 2 trial of single-agent bevacizumab given in an every-3-week schedule for patients with recurrent high-grade gliomas
- (2010) Jeffrey J. Raizer et al. CANCER
- Carboplatin and etoposide combined with bevacizumab for the treatment of recurrent glioblastoma multiforme
- (2010) Alessandra B. Francesconi et al. JOURNAL OF CLINICAL NEUROSCIENCE
- Enzastaurin in the Treatment of Recurrent Glioblastoma: A Promise That Did Not Materialize
- (2010) Evanthia Galanis et al. JOURNAL OF CLINICAL ONCOLOGY
- Effective Reduction of Gastric Cancer Risk With Regular Use of Nonsteroidal Anti-Inflammatory Drugs in Helicobacter Pylori–Infected Patients
- (2010) Chun-Ying Wu et al. JOURNAL OF CLINICAL ONCOLOGY
- Lack of Efficacy of Bevacizumab Plus Irinotecan in Children With Recurrent Malignant Glioma and Diffuse Brainstem Glioma: A Pediatric Brain Tumor Consortium Study
- (2010) Sridharan Gururangan et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase III Study of Enzastaurin Compared With Lomustine in the Treatment of Recurrent Intracranial Glioblastoma
- (2010) Wolfgang Wick et al. JOURNAL OF CLINICAL ONCOLOGY
- Predicting Adverse Events in Children With Fever and Chemotherapy-Induced Neutropenia: The Prospective Multicenter SPOG 2003 FN Study
- (2010) Roland A. Ammann et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase II Study of Cediranib, an Oral Pan–Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients With Recurrent Glioblastoma
- (2010) Tracy T. Batchelor et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase II Study of Bevacizumab Plus Temozolomide During and After Radiation Therapy for Patients With Newly Diagnosed Glioblastoma Multiforme
- (2010) Albert Lai et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase II study of metronomic chemotherapy with bevacizumab for recurrent glioblastoma after progression on bevacizumab therapy
- (2010) David A. Reardon et al. JOURNAL OF NEURO-ONCOLOGY
- Rebound tumour progression after the cessation of bevacizumab therapy in patients with recurrent high-grade glioma
- (2010) Richard M. Zuniga et al. JOURNAL OF NEURO-ONCOLOGY
- Population-based incidence and survival of central nervous system (CNS) malignancies in Girona (Spain) 1994–2005
- (2010) Rafael Fuentes-Raspall et al. JOURNAL OF NEURO-ONCOLOGY
- Recurrent spinal cord glioblastoma: salvage therapy with bevacizumab
- (2010) Marc C. Chamberlain et al. JOURNAL OF NEURO-ONCOLOGY
- Impact of bevacizumab chemotherapy on craniotomy wound healing
- (2010) Aaron J. Clark et al. JOURNAL OF NEUROSURGERY
- A phase I factorial design study of dose-dense temozolomide alone and in combination with thalidomide, isotretinoin, and/or celecoxib as postchemoradiation adjuvant therapy for newly diagnosed glioblastoma
- (2010) M. R. Gilbert et al. NEURO-ONCOLOGY
- Response as a predictor of survival in patients with recurrent glioblastoma treated with bevacizumab
- (2010) M. Prados et al. NEURO-ONCOLOGY
- OPTIC NEUROPATHY IN PATIENTS WITH GLIOBLASTOMA RECEIVING BEVACIZUMAB
- (2010) M. C. Chamberlain et al. NEUROLOGY
- Patterns of Care and Survival in a Retrospective Analysis of 1059 Patients With Glioblastoma Multiforme Treated Between 2002 and 2007: A Multicenter Study by the Central Nervous System Study Group of Airo (Italian Association of Radiation Oncology)
- (2010) Silvia Scoccianti et al. NEUROSURGERY
- Corticosteroid Use in Patients with Glioblastoma at First or Second Relapse Treated with Bevacizumab in the BRAIN Study
- (2010) J. J. Vredenburgh et al. ONCOLOGIST
- Metronomic chemotherapy with daily, oral etoposide plus bevacizumab for recurrent malignant glioma: a phase II study
- (2009) D A Reardon et al. BRITISH JOURNAL OF CANCER
- Safety and Efficacy of Bevacizumab With Hypofractionated Stereotactic Irradiation for Recurrent Malignant Gliomas
- (2009) Philip H. Gutin et al. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
- Bevacizumab Alone and in Combination With Irinotecan in Recurrent Glioblastoma
- (2009) Henry S. Friedman et al. JOURNAL OF CLINICAL ONCOLOGY
- Diffusion Magnetic Resonance Imaging Detects Pathologically Confirmed, Nonenhancing Tumor Progression in a Patient With Recurrent Glioblastoma Receiving Bevacizumab
- (2009) Elizabeth R. Gerstner et al. JOURNAL OF CLINICAL ONCOLOGY
- Salvage therapy with single agent bevacizumab for recurrent glioblastoma
- (2009) Marc C. Chamberlain et al. JOURNAL OF NEURO-ONCOLOGY
- Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial
- (2009) Roger Stupp et al. LANCET ONCOLOGY
- Role of a second chemotherapy in recurrent malignant glioma patients who progress on bevacizumab
- (2009) Eudocia C. Quant et al. NEURO-ONCOLOGY
- Bevacizumab and chemotherapy for recurrent glioblastoma: A single-institution experience
- (2009) P. L. Nghiemphu et al. NEUROLOGY
- OPTIC NEUROPATHY IN PATIENTS WITH GLIOBLASTOMA RECEIVING BEVACIZUMAB
- (2009) J. H. Sherman et al. NEUROLOGY
- Patterns of relapse and prognosis after bevacizumab failure in recurrent glioblastoma
- (2009) F. M. Iwamoto et al. NEUROLOGY
- FDA Drug Approval Summary: Bevacizumab (Avastin(R)) as Treatment of Recurrent Glioblastoma Multiforme
- (2009) M. H. Cohen et al. ONCOLOGIST
- Bevacizumab plus irinotecan in the treatment patients with progressive recurrent malignant brain tumours
- (2008) Hans Skovgaard Poulsen et al. ACTA ONCOLOGICA
- Clinical pharmacokinetics of bevacizumab in patients with solid tumors
- (2008) Jian-Feng Lu et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Phase II Trial of Single-Agent Bevacizumab Followed by Bevacizumab Plus Irinotecan at Tumor Progression in Recurrent Glioblastoma
- (2008) Teri N. Kreisl et al. JOURNAL OF CLINICAL ONCOLOGY
- Efficacy, safety and patterns of response and recurrence in patients with recurrent high-grade gliomas treated with bevacizumab plus irinotecan
- (2008) R. M. Zuniga et al. JOURNAL OF NEURO-ONCOLOGY
- Novel anti-angiogenic therapies for malignant gliomas
- (2008) Andrew D Norden et al. LANCET NEUROLOGY
- Malignant Gliomas in Adults
- (2008) Patrick Y. Wen et al. NEW ENGLAND JOURNAL OF MEDICINE
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started